Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,796 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pregnancy, Complications Clear all
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

NCT07749586
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ARV-6723, Pembrolizumab, SOC
Drug
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Terminated Not applicable Interventional

Early Versus Late Voiding Trials After Prolapse Repair

NCT02739256
View directory record Official record
Conditions
Urinary Retention, Pelvic Organ Prolapse
Interventions
Retrograde voiding trial
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 19, 2026, 5:29 PM EDT
Active, not recruiting No phase listed Observational

Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

NCT04919122
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
19 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Iowa City, Iowa • Kansas City, Kansas • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Telemonitoring to Improve Outcomes of Patients With Chronic Kidney Disease (CKD)

NCT01446029
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Video Telemonitoring Device with Clinical Care Modules
Device
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 19, 2026, 5:29 PM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03541902
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Cabozantinib, Sunitinib Malate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients

NCT00308802
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney transplantation
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 19, 2026, 5:29 PM EDT
Terminated Phase 2 Interventional Results available

Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

NCT00176501
View directory record Official record
Conditions
Kidney Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 19, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
138
States / cities
Birmingham, Alabama • Athens, Georgia • Augusta, Georgia + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD47M in Patients With Solid Tumors

NCT03957096
View directory record Official record
Conditions
Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma, Breast Carcinoma, Ovarian Carcinoma, Exocrine Pancreatic Carcinoma, Gastric Carcinoma, Melanoma
Interventions
SGN-CD47M
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Cleveland, Ohio • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

NCT02925962
View directory record Official record
Conditions
Hypertension, Renal Insufficiency, Chronic
Interventions
Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
542 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 19, 2026, 5:29 PM EDT
Recruiting No phase listed Observational

Rare Kidney Stone Consortium Patient Registry

NCT00588562
View directory record Official record
Conditions
Primary Hyperoxaluria, Dent Disease, Cystinuria, APRT Deficiency
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
0 Years to 100 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2028
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Completed No phase listed Observational

Sickle Cell Uric Acid (SCUA) - Cohort Repository

NCT04190888
View directory record Official record
Conditions
Chronic Kidney Diseases, Sickle Cell Disease
Interventions
No intervention
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
5 Years to 29 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 19, 2026, 5:29 PM EDT
Completed No phase listed Observational

Screening for Bladder Cancer

NCT00848627
View directory record Official record
Conditions
Bladder Cancer
Interventions
Specimen and questionnaires only
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
60 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 19, 2026, 5:29 PM EDT
Recruiting No phase listed Observational

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

NCT05909761
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, Pregnancy Related
Interventions
UPLIZNA
Drug
Lead sponsor
Amgen
Industry
Eligibility
15 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Not listed Not applicable Interventional

PREMOD2 With Near Infrared Spectroscopy Sub-study

NCT03145142
View directory record Official record
Conditions
Hypoxia, Brain, Premature Birth
Interventions
Umbilical cord milking, Delayed Cord Clamping
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 28 Weeks
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus

NCT00231842
View directory record Official record
Conditions
Uterine Cancer
Interventions
Ifosfamide, Radiation Therapy, Cisplatin
Drug · Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 19, 2026, 5:29 PM EDT
Not listed Phase 1Phase 2 Interventional

Effect of Testosterone Treatment on Embryo Quality

NCT01662466
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions
Testosterone cream (0.5mg per gram), DHEA, Placebo
Drug · Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
38 Years to 44 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 19, 2026, 5:29 PM EDT
Terminated Not applicable Interventional

Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer

NCT00856453
View directory record Official record
Conditions
Depression, Fatigue, Ovarian Cancer
Interventions
Home yoga practice, yoga classes
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Phase 2 Interventional

A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma

NCT00226980
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
Thalidomide, Capecitabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Sep 19, 2026, 5:29 PM EDT
Not yet recruiting Phase 2 Interventional

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

NCT07773727
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
ARGX-121, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Miami, Florida • Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Completed No phase listed Observational

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Chitosan
Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

NCT05299554
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
16 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 19, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 19, 2026, 5:29 PM EDT